论文部分内容阅读
目的:观察了解新型口服降糖药马来酸罗格列酮 (文迪雅 )单用或与二甲双胍、磺脲类合用的临床疗效。 方法:对 36例 2型糖尿病患者进行为期 12周的文迪雅治疗 ,包括单一用药组 (8例 )、合用二甲双胍组 (14例 )、合用磺脲组 (14例 )。 12周后测定患者空腹血糖 (FBG)、糖化血红蛋白 (Hb Alc)、空腹胰岛素 (FINS)、胰岛素抵抗指数 (HOMA)、血压及脂代谢指标。结果 :文迪雅治疗 12周后 ,患者 FBG、Hb Alc、FINS及 HOMA均下降 ,治疗后体重略有增加 ,总胆固醇 TC、高密度脂蛋白 (HDL- C)、低密度脂蛋白 (L DL- C)值增高 ,收缩压和舒张压降低。 结论 :文迪雅有明显的降低 2型糖尿病患者 FBG、FINS、Hb Alc及减少胰岛素抵抗的效果 ,是治疗 2型糖尿病有效和安全的口服降糖药物。
Objective: To observe and understand the clinical efficacy of rosiglitazone maleate (Avandia), a new oral antidiabetic drug, alone or in combination with metformin and sulfonylureas. Methods: 36 patients with type 2 diabetes were treated with Avandia for 12 weeks, including single treatment group (n = 8), metformin group (n = 14) and sulfonylureas group (n = 14). After 12 weeks, fasting blood glucose (FBG), Hb Alc, FINS, HOMA, blood pressure and lipid metabolism were measured. Results: After 12 weeks of Avandia treatment, the FBG, Hb Alc, FINS and HOMA decreased in all patients. After treatment, body weight slightly increased, total cholesterol TC, HDL-C and LDL- - C) Increased values of systolic and diastolic blood pressure. Conclusion: Avandia has obvious effect of reducing FBG, FINS and Hb Alc in patients with type 2 diabetes and reducing insulin resistance. It is an effective and safe oral antidiabetic drug for type 2 diabetes mellitus.